Study identifier:NIS-GKR-ATC-2011/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Recurrence rate, risk factors for the recurrence, and quality of life in patients with GERD in Korea-an observational study
The aim of this study is to investigate the frequency and related risk factors of recurrence, and quality of life in patients with GERD after treatment with PPI
-
No
-
All
855
Observational
20 Years - 80 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jul 2014 by AstraZeneca
AstraZeneca
-
Recurrence rate, risk factors for the recurrence, and quality of life in patients with GERD in Korea-an observational study.
Location
Location
Busan, Republic of Korea
Location
Daegu, Republic of Korea
Location
Daejeon, Republic of Korea
Location
Gangneung, Republic of Korea
Location
Goyang-si, Republic of Korea
Location
Gwangju, Republic of Korea
Location
Incheon, Republic of Korea
Location
Jeonju-si, Republic of Korea
Arms | Assigned Interventions |
---|---|
Typical reflux symptom by EGD Total 2000 subjects who has Typical reflux symptom by EGD | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.